BNP Paribas Financial Markets’s Entrada Therapeutics TRDA Stock Holding History

BNP Paribas Financial Markets’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.29M	Buy	181,148 +179	+0.1%	+$2.05K	﹤0.01%	2579
2025 Q4	$1.86M	Buy	180,969 +32,757	+22%	+$276K	﹤0.01%	2665
2025 Q3	$860K	Buy	148,212 +145,167	+4,767%	+$849K	﹤0.01%	3224
2025 Q2	$20.5K	Sell	3,045 -5,189	-63%	-$41.7K	﹤0.01%	4595
2025 Q1	$74.4K	Buy	8,234 +4,910	+148%	+$61.2K	﹤0.01%	4149
2024 Q4	$57.5K	Buy	+3,324	New	+$60.2K	﹤0.01%	4375
2022 Q4	–	Sell	-198	Closed	-$3.12K	–	4605
2022 Q3	$3.12K	Buy	+198	New	+$2.51K	﹤0.01%	4298

Other funds holding TRDA

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BNP Paribas Financial Markets's TRDA Position: Q1 2026 in Review

BNP Paribas Financial Markets increased its Entrada Therapeutics (TRDA) stake by 0.1% in Q1 2026, buying an estimated $2.05K and bringing the position to 181,148 shares worth $2.29M. The position accounts for ﹤0.01% of the portfolio, ranked #2579.

BNP Paribas Financial Markets first reported a position in TRDA in Q3 2022 and has held it in 7 quarters since. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

BNP Paribas Financial Markets held 181,148 shares of Entrada Therapeutics worth $2.29M as of Q1 2026.
BNP Paribas Financial Markets bought 179 Entrada Therapeutics shares in Q1 2026, an estimated $2.05K.
Entrada Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #2579 holding.
BNP Paribas Financial Markets first reported a position in Entrada Therapeutics in Q3 2022 and has held it in 7 quarters since.
120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.